Attenuating the HCC growth by blocking ROS and HMGB1 could be a therapeutic target.[45] In diethylnitrosamine‐treated mice model, the ATG5Mye-/- group was more likely to develop liver cancer and had a higher tumor burden and exhibits impaired immune cell recruitment and activation. This evidence concerns the gene HMGB1 and hepatocellular carcinoma.